JPWO2020023614A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020023614A5 JPWO2020023614A5 JP2021503813A JP2021503813A JPWO2020023614A5 JP WO2020023614 A5 JPWO2020023614 A5 JP WO2020023614A5 JP 2021503813 A JP2021503813 A JP 2021503813A JP 2021503813 A JP2021503813 A JP 2021503813A JP WO2020023614 A5 JPWO2020023614 A5 JP WO2020023614A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- pharmaceutical composition
- agents
- excipient
- inhaler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 100
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 43
- 239000003814 drug Substances 0.000 claims description 35
- 229940124597 therapeutic agent Drugs 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 11
- 229940121375 antifungal agent Drugs 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000003429 antifungal agent Substances 0.000 claims description 9
- 239000002105 nanoparticle Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 7
- 229960004740 voriconazole Drugs 0.000 claims description 7
- 229940112141 dry powder inhaler Drugs 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- -1 beta agonists Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 229940071648 metered dose inhaler Drugs 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims description 2
- 206010021639 Incontinence Diseases 0.000 claims description 2
- 229940124091 Keratolytic Drugs 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 229940035674 anesthetics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 230000000507 anthelmentic effect Effects 0.000 claims description 2
- 229940124339 anthelmintic agent Drugs 0.000 claims description 2
- 239000000921 anthelmintic agent Substances 0.000 claims description 2
- 239000004004 anti-anginal agent Substances 0.000 claims description 2
- 229940127003 anti-diabetic drug Drugs 0.000 claims description 2
- 239000000883 anti-obesity agent Substances 0.000 claims description 2
- 230000003262 anti-osteoporosis Effects 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 2
- 239000000924 antiasthmatic agent Substances 0.000 claims description 2
- 229940124350 antibacterial drug Drugs 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 239000000729 antidote Substances 0.000 claims description 2
- 239000002111 antiemetic agent Substances 0.000 claims description 2
- 229960002708 antigout preparations Drugs 0.000 claims description 2
- 239000003430 antimalarial agent Substances 0.000 claims description 2
- 229940125684 antimigraine agent Drugs 0.000 claims description 2
- 239000002282 antimigraine agent Substances 0.000 claims description 2
- 229940125710 antiobesity agent Drugs 0.000 claims description 2
- 239000000939 antiparkinson agent Substances 0.000 claims description 2
- 239000003904 antiprotozoal agent Substances 0.000 claims description 2
- 239000003200 antithyroid agent Substances 0.000 claims description 2
- 229940043671 antithyroid preparations Drugs 0.000 claims description 2
- 239000003434 antitussive agent Substances 0.000 claims description 2
- 229940124584 antitussives Drugs 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 239000002830 appetite depressant Substances 0.000 claims description 2
- 229940125388 beta agonist Drugs 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims description 2
- 230000019771 cognition Effects 0.000 claims description 2
- 229940000425 combination drug Drugs 0.000 claims description 2
- 229940124558 contraceptive agent Drugs 0.000 claims description 2
- 239000003433 contraceptive agent Substances 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 229940111134 coxibs Drugs 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000003172 expectorant agent Substances 0.000 claims description 2
- 230000003419 expectorant effect Effects 0.000 claims description 2
- 239000004083 gastrointestinal agent Substances 0.000 claims description 2
- 229940127227 gastrointestinal drug Drugs 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 239000005555 hypertensive agent Substances 0.000 claims description 2
- 239000003326 hypnotic agent Substances 0.000 claims description 2
- 230000000147 hypnotic effect Effects 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000001530 keratinolytic effect Effects 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 239000003149 muscarinic antagonist Substances 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- 239000000014 opioid analgesic Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 229940125723 sedative agent Drugs 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 150000005846 sugar alcohols Chemical group 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229940066493 expectorants Drugs 0.000 claims 1
- 239000003410 keratolytic agent Substances 0.000 claims 1
- 229940041033 macrolides Drugs 0.000 claims 1
- 229940035363 muscle relaxants Drugs 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 45
- 239000002904 solvent Substances 0.000 description 12
- 239000003960 organic solvent Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical group C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024154560A JP2024170583A (ja) | 2018-07-24 | 2024-09-09 | 超高速凍結による表面改質された治療活性粒子の組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702674P | 2018-07-24 | 2018-07-24 | |
| US62/702,674 | 2018-07-24 | ||
| PCT/US2019/043202 WO2020023614A1 (en) | 2018-07-24 | 2019-07-24 | Compositions of surface-modified therapeutically active particles by ultra-rapid freezing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024154560A Division JP2024170583A (ja) | 2018-07-24 | 2024-09-09 | 超高速凍結による表面改質された治療活性粒子の組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021530551A JP2021530551A (ja) | 2021-11-11 |
| JP2021530551A5 JP2021530551A5 (https=) | 2022-08-01 |
| JPWO2020023614A5 true JPWO2020023614A5 (https=) | 2022-08-01 |
| JP7611813B2 JP7611813B2 (ja) | 2025-01-10 |
Family
ID=69181152
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503813A Active JP7611813B2 (ja) | 2018-07-24 | 2019-07-24 | 超高速凍結による表面改質された治療活性粒子の組成物 |
| JP2024154560A Pending JP2024170583A (ja) | 2018-07-24 | 2024-09-09 | 超高速凍結による表面改質された治療活性粒子の組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024154560A Pending JP2024170583A (ja) | 2018-07-24 | 2024-09-09 | 超高速凍結による表面改質された治療活性粒子の組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210338671A1 (https=) |
| EP (1) | EP3827260A4 (https=) |
| JP (2) | JP7611813B2 (https=) |
| KR (1) | KR20210038583A (https=) |
| CN (1) | CN112673257B (https=) |
| AU (1) | AU2019311086A1 (https=) |
| BR (1) | BR112021001290A2 (https=) |
| CA (1) | CA3106618A1 (https=) |
| EA (1) | EA202190331A1 (https=) |
| IL (1) | IL280342A (https=) |
| MX (1) | MX2021000796A (https=) |
| WO (1) | WO2020023614A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014186754A2 (en) | 2013-05-16 | 2014-11-20 | Board Of Regents The University Of Texas System | Dry solid aluminum adjuvant-containing vaccines and related methods thereof |
| US11918646B2 (en) | 2017-12-11 | 2024-03-05 | Board Of Regents, The University Of Texas System | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration |
| CN113398079B (zh) * | 2020-03-16 | 2024-01-19 | 鲁南制药集团股份有限公司 | 一种注射用氟达拉滨冻干粉 |
| BR112023001929A2 (pt) | 2020-09-03 | 2023-03-14 | Philip Morris Products Sa | Composições em pó ativas de baixa higroscopicidade |
| US20230301919A1 (en) * | 2020-09-03 | 2023-09-28 | Philip Morris Products S.A. | Freeze dried low hygroscopicity active powder compositions |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| CN117241786A (zh) * | 2021-03-12 | 2023-12-15 | 德克萨斯大学系统董事会 | 使用基于悬浮液的薄膜冷冻制备干燥粉末的方法 |
| US12015755B2 (en) | 2021-03-25 | 2024-06-18 | Korea Advanced Institute Of Science And Technology | Real-time omnidirectional stereo matching method using multi-view fisheye lenses and system thereof |
| CN113484469B (zh) * | 2021-06-30 | 2022-11-18 | 中国科学院青海盐湖研究所 | 水合盐体系相变储能材料纳米尺度相分离的原位表征方法 |
| CN116440084A (zh) * | 2022-01-07 | 2023-07-18 | 浙江萃泽医药科技有限公司 | 一种可吸入的药物粉末制剂及其制备方法 |
| AU2023366929A1 (en) | 2022-10-25 | 2025-05-08 | Veradermics, Incorporated | Compositions and methods of use for modified release minoxidil |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08310969A (ja) * | 1995-05-22 | 1996-11-26 | Lion Corp | 固形薬品組成物及びその製造方法 |
| US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| CN1750811A (zh) * | 2001-10-19 | 2006-03-22 | 巴克斯特国际公司 | 在冷冻水基质中包括颗粒的稳定组合物 |
| GB0321607D0 (en) * | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| US9061027B2 (en) * | 2004-08-27 | 2015-06-23 | Board Of Regents, The University Of Texas System | Enhanced delivery of drug compositions to treat life threatening infections |
| WO2007011396A2 (en) * | 2004-10-29 | 2007-01-25 | President And Fellows Of Harvard College | Particles for treatment of pulmonary infection |
| US8361439B1 (en) * | 2005-01-04 | 2013-01-29 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| WO2007053923A2 (en) * | 2005-11-11 | 2007-05-18 | Biolab Sanus Farmacêutica Ltda. | Solid pharmaceutical composition comprising agglomerate nanoparticles and a process for producing the same |
| WO2011046842A1 (en) * | 2009-10-12 | 2011-04-21 | The Regents Of The University Of California | Targeted nanoclusters and methods of their use |
| US10973763B2 (en) * | 2011-06-17 | 2021-04-13 | Berg Llc | Inhalable pharmaceutical compositions |
| US9801855B2 (en) * | 2012-03-07 | 2017-10-31 | National Institute Of Pharmaceutical Education And Research (Niper) | Nanocrystalline solid dispersion compositions and process of preparation thereof |
| JP6940416B2 (ja) * | 2015-05-01 | 2021-09-29 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 多剤脆性マトリックス組成物 |
-
2019
- 2019-07-24 JP JP2021503813A patent/JP7611813B2/ja active Active
- 2019-07-24 AU AU2019311086A patent/AU2019311086A1/en active Pending
- 2019-07-24 CN CN201980055623.XA patent/CN112673257B/zh active Active
- 2019-07-24 CA CA3106618A patent/CA3106618A1/en active Pending
- 2019-07-24 US US17/262,313 patent/US20210338671A1/en active Pending
- 2019-07-24 EA EA202190331A patent/EA202190331A1/ru unknown
- 2019-07-24 WO PCT/US2019/043202 patent/WO2020023614A1/en not_active Ceased
- 2019-07-24 MX MX2021000796A patent/MX2021000796A/es unknown
- 2019-07-24 KR KR1020217005060A patent/KR20210038583A/ko not_active Ceased
- 2019-07-24 BR BR112021001290-7A patent/BR112021001290A2/pt unknown
- 2019-07-24 EP EP19840589.6A patent/EP3827260A4/en active Pending
-
2021
- 2021-01-21 IL IL280342A patent/IL280342A/en unknown
-
2024
- 2024-09-09 JP JP2024154560A patent/JP2024170583A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530551A5 (https=) | ||
| Kumar et al. | Mucoadhesive carriers for oral drug delivery | |
| JPWO2020023614A5 (https=) | ||
| ES2691033T3 (es) | Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios | |
| ES2387749T3 (es) | Aerosoles que comprenden fármacos nanoparticulados | |
| Mittal et al. | Insights into direct nose to brain delivery: current status and future perspective | |
| EP0386232B1 (en) | Nasal administration of benzodiazepine hypnotics | |
| CN112673257B (zh) | 通过超快速冷冻制得的表面改性的治疗活性颗粒的组合物 | |
| ES2953878T3 (es) | Composición que comprende al menos dos polvos secos obtenidos mediante secado por aspersión para aumentar la estabilidad de la formulación | |
| ES2896971T3 (es) | Formas de administración de hormona del crecimiento de acción prolongada | |
| BR112012023324B1 (pt) | Processo de preparação de uma forma de dosagem multifásica liofilizada de dissolução rápida | |
| JP2017048250A5 (https=) | ||
| ES2582287B1 (es) | Procedimiento de obtención y composición farmacéutica de nanopartículas polimericas para el tratamiento de dolor neuropático producido por compresión nerviosa periférica | |
| Doroudian et al. | Nano-based therapies for acute and chronic lung diseases | |
| TWI494133B (zh) | 重組用粉末 | |
| US20180177744A1 (en) | Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine | |
| WO2016199170A2 (en) | Paliperidone palmitate particles and compositions thereof | |
| JP2001524963A (ja) | 卵巣癌を治療するための方法及び組成物 | |
| CN100418526C (zh) | 依贝沙坦在制备用来预防或治疗肺动脉高压的药物中的应用 | |
| EP3463298B1 (en) | Metronomic oral gemcitabine for cancer therapy | |
| KR20250127236A (ko) | 닌테다닙 및 닌테다닙 조합 건조 분말 조성물 및 용도 | |
| TWI296928B (en) | Medicaments comprising betamimetics and a novel anticholinergic | |
| KR et al. | ADVANCEMENT IN BUCCAL DRUG DELIVERY FOR CONVENIENT ORAL INSULIN ADMINISTRATION | |
| Carter | Pharmacological Implications of Drug Administration Routes | |
| Abdullah et al. | A OVERVIEW OF NASAL TO BRAIN DRUG DELIVERY |